Brazilian liver cancer study reveals Real-World treatment patterns

NCT ID NCT06230328

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study reviewed medical records of 300 liver cancer patients treated in Brazil between 2017 and 2022. Researchers aimed to understand patient characteristics, how the cancer was managed, and survival outcomes. No new treatments were tested; instead, the goal was to gather real-world evidence to improve future care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA HEPATOCELLULAR CARCINOMA BY BCLC STAGE HEPATOCELLULAR CARCINOMA STAGE I HEPATOCELLULAR CARCINOMA STAGE II HEPATOCELLULAR CARCINOMA STAGE III

Contacts and locations

Show contact details

Locations

Research Site

Barretos, Brazil
Research Site

Belo Horizonte, Brazil
Research Site

Curitiba, Brazil
Research Site

Natal, Brazil
Research Site

Porto Alegre, Brazil
Research Site

Recife, Brazil
Research Site

Rio de Janeiro, Brazil
Research Site

Salvador, Brazil
Research Site

São Bernardo do Campo, Brazil
Research Site

São Paulo, Brazil
Research Site

Vitória, Brazil